Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Deferred Revenue (2016 - 2025)

Collegium Pharmaceutical has reported Current Deferred Revenue over the past 7 years, most recently at $667000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $667000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $667000.0 (changed N/A YoY), and the annual figure for FY2025 was $667000.0, changed.
  • Current Deferred Revenue for Q4 2025 was $667000.0 at Collegium Pharmaceutical, roughly flat from $667000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for COLL hit a ceiling of $172.4 million in Q2 2025 and a floor of $667000.0 in Q3 2025.
  • Median Current Deferred Revenue over the past 5 years was $29.4 million (2024), compared with a mean of $64.1 million.
  • Peak annual rise in Current Deferred Revenue hit 688.15% in 2025, while the deepest fall reached 97.73% in 2025.
  • Collegium Pharmaceutical's Current Deferred Revenue stood at $13.2 million in 2021, then skyrocketed by 456.13% to $73.6 million in 2022, then soared by 103.7% to $149.8 million in 2023, then tumbled by 80.36% to $29.4 million in 2024, then plummeted by 97.73% to $667000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $667000.0 (Q4 2025), $667000.0 (Q3 2025), and $172.4 million (Q2 2025) per Business Quant data.